Pfizer just reported its #vaccine doesn’t perform well in 2-5 year-olds.
This is what science looks like: we get mixed findings and try to communicate with transparency.
Lots of parents want protection for their kids. Stay tuned. ❤️
— Scott Hadland, MD (@DrScottHadland) December 17, 2021
Pfizer is applying to modify their protocol to add a third shot to the sequence to see if they can get an antibody reaction similar to older kids and adults for this age group.